HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Video

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Paul Szabolcs, MD, discusses data from the following study:

  • Hematopoietic Stem Cell Transplantation (HSCT) With Omidubicel Is Associated With Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to Standard Umbilical Cord Blood [UCB] Transplantation (ASH 2021, Dec 11-14. Abstract 333)
    • The objective of this study is to report the efficacy of HSCT with omidubicel as compared to standard umbilical cord blood transplantation in patients with hematologic malignancies.
    • The limitations of cord blood transplantation are delayed hematopoietic and immune recovery and increased transplant-related mortality, although a robust recovery of NK [natural killer] cells is evident.
    • Omidubicel is an advanced cell therapy for allogeneic HSCT that preserves stem cell function to optimize homing, engraftment, and differentiation.
    • Conclusions:
      • HSCT with omidubicel results in rapid hematopoietic recovery, reduced rates of infections, and no increase in GvHD [graft-versus-host disease] rates compared with standard UCB transplantation.
      • In the immediate post-transplant period, immune cell recovery was significantly faster with omidubicel compared with standard UCB transplantation despite receiving a lower number of T cells at transplant.
      • Enhanced recovery of circulatory mDC [myeloid dendritic cells], pDC [plasmacytoid dendritic cells], NK, and CD4+ T cells within the first 28 days, and sustained B-cell recovery from Day 28 through the first year, were observed.
      • These results demonstrate rapid and functional reconstitution of T- and B-cell subsets following transplant with omidubicel, which provides mechanistic support for the lower rates of severe infection observed in the omidubicel-treated patients.
Related Videos
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute
© 2024 MJH Life Sciences

All rights reserved.